Oncopeptides AB (publ) (ONCO.ST)
SEK 1.54
(1.18%)
SEK 1.54
(1.18%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1.96 SEK | 52.31% |
| 2022 | -4.11 SEK | 78.37% |
| 2021 | -19.00 SEK | 25.69% |
| 2020 | -25.57 SEK | -78.44% |
| 2019 | -14.33 SEK | -46.67% |
| 2018 | -9.77 SEK | -52.9% |
| 2017 | -6.39 SEK | -116.61% |
| 2016 | -2.95 SEK | -115.33% |
| 2015 | -1.37 SEK | -61.18% |
| 2014 | -0.85 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.53 SEK | 41.11% |
| 2024 Q2 | -0.35 SEK | 9.43% |
| 2023 Q2 | -0.62 SEK | 21.52% |
| 2023 FY | - SEK | 52.31% |
| 2023 Q4 | -0.90 SEK | -100.0% |
| 2023 Q3 | -0.45 SEK | 27.42% |
| 2023 Q1 | -0.79 SEK | 21.78% |
| 2022 Q1 | -1.31 SEK | 73.21% |
| 2022 FY | - SEK | 78.37% |
| 2022 Q2 | -0.79 SEK | 39.69% |
| 2022 Q4 | -1.01 SEK | -1.0% |
| 2022 Q3 | -1.00 SEK | -26.58% |
| 2021 Q2 | -0.32 SEK | 90.72% |
| 2021 Q1 | -3.45 SEK | 54.84% |
| 2021 FY | - SEK | 25.69% |
| 2021 Q3 | -10.33 SEK | -3128.13% |
| 2021 Q4 | -4.89 SEK | 52.66% |
| 2020 Q2 | -6.79 SEK | -26.44% |
| 2020 FY | - SEK | -78.44% |
| 2020 Q4 | -7.64 SEK | -33.8% |
| 2020 Q1 | -5.37 SEK | -17.76% |
| 2020 Q3 | -5.71 SEK | 15.91% |
| 2019 Q4 | -4.56 SEK | -29.18% |
| 2019 Q3 | -3.53 SEK | -0.28% |
| 2019 Q2 | -3.52 SEK | -36.96% |
| 2019 Q1 | -2.57 SEK | -1.58% |
| 2019 FY | - SEK | -46.67% |
| 2018 FY | - SEK | -52.9% |
| 2018 Q4 | -2.53 SEK | -8.12% |
| 2018 Q3 | -2.34 SEK | 28.22% |
| 2018 Q1 | -1.56 SEK | 7.14% |
| 2018 Q2 | -3.26 SEK | -108.97% |
| 2017 Q3 | -1.30 SEK | 23.08% |
| 2017 FY | - SEK | -116.61% |
| 2017 Q4 | -1.68 SEK | -29.23% |
| 2017 Q2 | -1.69 SEK | 10.58% |
| 2017 Q1 | -1.89 SEK | -44.27% |
| 2016 Q4 | -1.31 SEK | -104.69% |
| 2016 FY | - SEK | -115.33% |
| 2016 Q3 | -0.64 SEK | -6.67% |
| 2016 Q2 | -0.60 SEK | -53.85% |
| 2016 Q1 | -0.39 SEK | 0.0% |
| 2015 FY | - SEK | -61.18% |
| 2014 FY | - SEK | 0.0% |